Literature DB >> 17725424

Drug resistance in plasma and breast milk after single-dose nevirapine in subtype C HIV type 1: population and clonal sequence analysis.

Seble Kassaye1, Esther Lee, Rami Kantor, Elizabeth Johnston, Mark Winters, Lynn Zijenah, Patrick Mateta, David Katzenstein.   

Abstract

Single-dose nevirapine (SD NVP) reduces intrapartum HIV-1 transmission, but nonnucleoside reverse transcription (NNRTI) resistance mutations can emerge. Population sequencing among 32 subtype C HIV-1-infected, SD NVP-exposed Zimbawean women demonstrated NNRTI resistance in 25/32 (78%) women: 23/30 (77%) at 2 weeks, 11/31 (35%) at 8 weeks, and 5/27 (19%) at 24 weeks. A total of 447 unique TA clones (median = 28 per time point), from four women with resistance at 8 weeks but wild-type virus by population sequence at 24 weeks, identified NNRTI mutations in a median of 76% (range: 55-96%) of individual clones at 2 weeks, 48% (range: 33-80%) at 8 weeks, and 5% (range: 0-15%) by 24 weeks. NNRTI mutations in breast milk clones at 2 and weeks from one woman varied significantly from plasma. Population sequencing underestimates the diversity of NNRTI resistance mutations within minority populations following SD NVP in subtype C HIV-1 viral RNA in plasma and breast milk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17725424     DOI: 10.1089/aid.2007.0045

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  15 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Phenotypic analysis of HIV-1 genotypic drug-resistant isolates from China, using a single-cycle system.

Authors:  Zheng Jia; Sihong Xu; Jianhui Nie; Jingyun Li; Ping Zhong; Wenbo Wang; Youchun Wang
Journal:  Mol Diagn Ther       Date:  2011-10-01       Impact factor: 4.074

3.  Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.

Authors:  Sherry L Farr; Julie A E Nelson; Thokozani J Ng'ombe; Athena P Kourtis; Charles Chasela; Jeffrey A Johnson; Angela D M Kashuba; Gerald L Tegha; Jeffrey Wiener; Joseph J Eron; Harriet N Banda; Mwanangwa Mpaso; Jonathan Lipscomb; Chrissie Matiki; Susan A Fiscus; Denise J Jamieson; Charles van der Horst
Journal:  J Acquir Immune Defic Syndr       Date:  2010-08       Impact factor: 3.731

4.  Evolution and molecular epidemiology of subtype C HIV-1 in Zimbabwe.

Authors:  Sudeb C Dalai; Tulio de Oliveira; Gordon W Harkins; Seble G Kassaye; Jennifer Lint; Justen Manasa; Elizabeth Johnston; David Katzenstein
Journal:  AIDS       Date:  2009-11-27       Impact factor: 4.177

5.  Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.

Authors:  Sarah E Hudelson; Michelle S McConnell; Danstan Bagenda; Estelle Piwowar-Manning; Teresa L Parsons; Monica L Nolan; Paul M Bakaki; Michael C Thigpen; Michael Mubiru; Mary Glenn Fowler; Susan H Eshleman
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

6.  Short communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding site epitopes.

Authors:  Elizabeth S Russell; Suany Ojeda; Genevieve G Fouda; Steven R Meshnick; David Montefiori; Sallie R Permar; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2013-01-18       Impact factor: 2.205

7.  Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission.

Authors:  Jessica D Church; Saad B Omer; Laura A Guay; Wei Huang; Jessica Lidstrom; Philippa Musoke; Francis Mmiro; J Brooks Jackson; Susan H Eshleman
Journal:  J Infect Dis       Date:  2008-10-01       Impact factor: 5.226

8.  Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

Authors:  Vici Varghese; Rajin Shahriar; Soo-Yon Rhee; Tommy Liu; Birgitte B Simen; Michael Egholm; Bozena Hanczaruk; Lisbeth A Blake; Baback Gharizadeh; Farbod Babrzadeh; Michael H Bachmann; W Jeffrey Fessel; Robert W Shafer
Journal:  J Acquir Immune Defic Syndr       Date:  2009-11-01       Impact factor: 3.731

9.  Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.

Authors:  Dara A Lehman; Michael H Chung; Jennifer M Mabuka; Grace C John-Stewart; James Kiarie; John Kinuthia; Julie Overbaugh
Journal:  J Acquir Immune Defic Syndr       Date:  2009-08-15       Impact factor: 3.731

10.  Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.

Authors:  Anitha Moorthy; Amita Gupta; Ramesh Bhosale; Srikanth Tripathy; Jayagowri Sastry; Smita Kulkarni; Madhuri Thakar; Renu Bharadwaj; Anju Kagal; Arvind V Bhore; Sandesh Patil; Vandana Kulkarni; Varadharajan Venkataramani; Usha Balasubramaniam; Nishi Suryavanshi; Carrie Ziemniak; Nikhil Gupte; Robert Bollinger; Deborah Persaud
Journal:  PLoS One       Date:  2009-01-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.